Advanced search×

Accessibility to targeted oncology drugs in Slovenia and selected European countries

Mitja M Kos, Marko M Obradovic, and Ales A Mrhar

Eur J Cancer 44(3):11 (2008) PMID 18155900

Aim: The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods: Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results: The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion: The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.

DOI: 10.1016/j.ejca.2007.11.020
Version: za2963e q8za4 q8zb8 q8zc8 q8zd5 q8zea q8zfd q8zg9
Buy PDF

Similar articles you may find interesting…

  1. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Prithviraj Bose, Gary L Simmons, and Steven Grant

    Expert Opin Investig Drugs (2013) PMID 23647051

    Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition ca...
    Buy PDF
  2. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?
    Susan E Craword, Philip Fitchev, and Olga V Volpert

    Expert Opin Drug Discov (2013) PMID 23642051

    Pigment epithelium-derived factor (PEDF) was discovered as a neurotrophic factor secreted by retinal pigment epithelial cells. A decade later, it re-emerged as a powerful angiogenesis inhibitor guarding ocular function. Since then, significant advances were made identifying PEDF's mechanisms, target...
    Buy PDF
  3. A Phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced ha...
    Gert J Ossenkoppele, Bob Lowenberg, and Phillip M Debnam

    Br J Haematol (2013) PMID 23647373

    Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi). This first-in-human, standard 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to determine the safety, tolerability, pharmacokinetic and pharmacodynamic profile o...
    Buy PDF